Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single Ascending Dose Tolerability Study of Veldoreotide
NCT02217488Phase 1Completed
- Sponsor
- Aspireo Pharmaceuticals Ltd.
- Start
- May 2008
- Primary completion
- Sep 2008
- Modality
- Peptides, Recombinant Proteins and Enzymes
01
Overview
Phase 1, randomised, double-blind trial in acromegaly comparing DG3173 with Vehicle (2 arms). Primary endpoint: Number of serious adverse events or withdrawals due to adverse events at 1 week. Started May 2008; status: completed.
02
Drugs
veldoreotide
03
Conditions
acromegaly
Beyond the preview
Go deeper on NCT02217488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02217488.